Alnylam Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Alnylam Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Alnylam Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Alnylam Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Alnylam Pharmaceuticals Inc (Alnylam Pharmaceuticals) is a biopharmaceutical company that discovers, develops, and commercializes drugs based on RNAi interference. The company’s marketed RNAi therapies include Onpattro, which is used in the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis, hATTR amyloidosis; Givlaari for acute hepatic porphyria; Amvuttra, for the treatment of ATTR amyloidosis with cardiomyopathy; and Oxlumo for primary hyperoxaluria type 1 (PH1). The company develops a broad pipeline that includes Onpatro, Amvuttra, Givlaari, Oxlumo, Leqvio, Vutrisiran, and others in clinical development. The company operates subsidiaries in Europe, North America, and Asia-Pacific. Alnylam Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
675 W Kendall St, Cambridge, Massachusetts, 02142-1168
Website
www.alnylam.com
Telephone
1 302 6587581
No of Employees
2,500
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ALNY (NASD)
Revenue (2024)
$3.7B
65.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
212.8%
(2024 vs 2023)
Market Cap*
$40.2B
Net Profit Margin (2024)
XYZ
168.3%
(2024 vs 2023)
* As of and is in US$
Alnylam Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Marketed: | Qfitlia |
| Onpattro - RNAi therapeutic for treatment of hATTR amyloidosis | Onpattro |
| Givlaari - Acute Hepatic Porphyria | Oxlumo |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Plans/Strategy | In December, the company announced its plans to open a new manufacturing facility in Norton, Massachusetts, the US. |
| 2025 | Regulatory Approval | In June, the company secured approval from the European Commission for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). |
| 2025 | Regulatory Approval | In March, the company received approval from the US FDA for Qfitlia (fitusiran), a RNAi Therapeutic) for the treatment of Hemophilia A or B. |
Competitor Comparison
| Key Parameters | Alnylam Pharmaceuticals Inc | Eli Lilly and Co | AstraZeneca Plc | Novo Nordisk AS | GSK plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | Denmark | United Kingdom |
| City | Cambridge | Indianapolis | Cambridge | Bagsvaerd | London |
| State/Province | Massachusetts | Indiana | Cambridgeshire | - | England |
| No. of Employees | 2,500 | 50,605 | 96,100 | 64,974 | 66,841 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Yvonne L. Greenstreet, M.D. | Chief Executive Officer; Director | Executive Board | 2022 | 63 |
| Amy W. Schulman | Chair | Executive Board | 2023 | 65 |
| Jeffrey V. Poulton | Chief Financial Officer; Executive Vice President | Senior Management | 2019 | 58 |
| Bryan Supran | Executive Vice President; Chief Legal Officer | Senior Management | - | 55 |
| Piyush Sharma | Chief Ethics Officer; Chief Compliance Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer